Protein kinases play crucial roles in the regulation of multiple cell signaling pathways and cellular functions. Deregulation of protein kinase function has been implicated in carcinogenesis. The inhibition of protein kinases has emerged as an important target for cancer chemoprevention and therapy. Accumulated data revealed that flavonoids exert chemopreventive effects through acting at protein kinase signaling pathways, more than as conventional hydrogen-donating antioxidants. Recent studies show that flavonoids can bind directly to some protein kinases, including Akt/protein kinase B (Akt/PKB), Fyn, Janus kinase 1 (JAK1), mitogen-activated protein kinase kinase 1 (MEK1), phosphoinositide 3-kinase (PI3K), mitogen-activated protein (MAP) kinase kinase 4 (MKK4), Raf1, and ζ chain-associated 70-kDa protein (ZAP-70) kinase, and then alter their phosphorylation state to regulate multiple cell signaling pathways in carcinogenesis processes. In this review, we report recent results on the interactions of flavonoids and protein kinases, especially their direct binding and molecular modeling. The data suggest that flavonoids act as protein kinase inhibitors for cancer chemoprevention that were thought previously as conventional hydrogen-donating antioxidant. Moreover, the molecular modeling data show some hints for creating natural compound-based protein kinase inhibitors for cancer chemoprevention and therapy. Antioxid. Redox Signal. 13, 691–719.
Abd El MohsenMM, KuhnleG, RechnerAR, SchroeterH, RoseS, JennerP, Rice–EvansCA. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med, 33:1693–1702. 2002.
2.
AdamsJA. Activation loop phosphorylation and catalysis in protein kinases: Is there functional evidence for the autoinhibitor model?Biochemistry, 42:601–607. 2003.
3.
AggarwalBB, BhardwajA, AggarwalRS, SeeramNP, ShishodiaS, TakadaY. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res, 24:2783–2840. 2004.
4.
AggarwalBB, IchikawaH. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle, 4:1201–1215. 2005.
5.
AggarwalBB, KumarA, BhartiAC. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res, 23:363–398. 2003.
6.
AggarwalBB, SethiG, BaladandayuthapaniV, KrishnanS, ShishodiaS. Targeting cell signaling pathways for drug discovery: An old lock needs a new key. J Cell Biochem, 102:580–592. 2007.
7.
AggarwalBB, ShishodiaS. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol, 71:1397–1421. 2006.
8.
AggarwalBB, SungB. Pharmacological basis for the role of curcumin in chronic diseases: An age-old spice with modern targets. Trends Pharmaco Sci, 30:85–94. 2008.
9.
AgulloG, Gamet–PayrastreL, ManentiS, VialaC, RemesyC, ChapH, PayrastreB. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: A comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol, 53:1649–1657. 1997.
10.
AlessiDR, AndjelkovicM, CaudwellB, CronP, MorriceN, CohenP, HemmingsBA. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J, 15:6541–6551. 1996.
11.
AlessiDR, SaitoY, CampbellDG, CohenP, SithanandamG, RappU, AshworthA, MarshallCJ, CowleyS. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J, 13:1610–1619. 1994.
12.
AltomareDA, TestaJR. Perturbations of the AKT signaling pathway in human cancer. Oncogene, 24:7455–7464. 2005.
13.
AroraA, ScholarEM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther, 315:971–979. 2005.
14.
AtharM, BackJH, TangX, KimKH, KopelovichL, BickersDR, KimAL. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol, 224:274–283. 2007.
15.
AtkinsonC, FrankenfeldCL, LampeJW. Gut bacterial metabolism of the soy isoflavone daidzein: Exploring the relevance to human health. Exp Biol Med (Maywood), 230:155–170. 2005.
BogoyevitchMA, FairlieDP. A new paradigm for protein kinase inhibition: Blocking phosphorylation without directly targeting ATP binding. Drug Discovery Today, 12:622–633. 2007.
20.
BonniA, BrunetA, WestAE, DattaSR, TakasuMA, GreenbergME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science, 286:1358–1362. 1999.
21.
BowmanT, GarciaR, TurksonJ, JoveR. STATs in oncogenesis. Oncogene, 19:2474–2488. 2000.
22.
BradshawL. Understanding piezoelectric quartz crystals. RF time and freq, 8:50–58. 2000.
23.
BrombergJ, DarnellJEJr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene, 19:2468–2473. 2000.
24.
BrunetA, BonniA, ZigmondMJ, LinMZ, JuoP, HuLS, AndersonMJ, ArdenKC, BlenisJ, GreenbergME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96:857–868. 1999.
25.
CamandolaS, PoliG, MattsonMP. The lipid peroxidation product 4-hydroxy-2,3-nonenal increases AP-1-binding activity through caspase activation in neurons. J Neurochem, 74:159–168. 2000.
26.
CantleyLC, NeelBG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway. Proc Natl Acad Sci USA, 96:4240–4245. 1999.
27.
CardoneMH, RoyN, StennickeHR, SalvesenGS, FrankeTF, StanbridgeE, FrischS, ReedJC. Regulation of cell death protease caspase-9 by phosphorylation. Science, 282:1318–1321. 1998.
28.
CastagneV, ClarkePG. Inhibitors of mitogen-activated protein kinases protect axotomized developing neurons. Brain Res, 842:215–219. 1999.
29.
This reference has been deleted.
30.
ChanAC, IrvingBA, FraserJD, WeissA. The zeta chain is associated with a tyrosine kinase and upon T-cell antigen receptor stimulation associates with ZAP-70, a 70-kDa tyrosine phosphoprotein. Proc Natl Acad Sci USA, 88:9166–9170. 1991.
31.
ChanAC, IwashimaM, TurckCW, WeissA. ZAP-70: A 70kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell, 71:649–662. 1992.
32.
ChanK, KanYW. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc Natl Acad Sci USA, 96:12731–12736. 1999.
33.
ChangF, LeeJT, NavolanicPM, SteelmanLS, SheltonJG, BlalockWL, FranklinRA, McCubreyJA. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia, 17:590–603. 2003.
34.
ChangF, SteelmanLS, LeeJT, SheltonJG, NavolanicPM, BlalockWL, FranklinRA, McCubreyJA. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention. Leukemia, 17:1263–1293. 2003.
35.
CheethamGM. Novel protein kinases and molecular mechanisms of autoinhibition. Curr Opin Struct Biol, 14:700–705. 2004.
36.
ChenC, KongAN. Dietary cancer-chemopreventive compounds: From signaling and gene expression to pharmacological effects. Trends Pharmacol Sci, 26:318–326. 2005.
ChoES, JangYJ, KangNJ, HwangMK, KimYT, LeeKW, LeeHJ. Cocoa procyanidins attenuate 4-hydroxynonenal-induced apoptosis of PC12 cells by directly inhibiting mitogen-activated protein kinase kinase 4 activity. Free Radic Biol Med, 46:1319–1327. 2009.
39.
ChoiYS, RyuBK, MinHK, LeeSW, PakYK. Analysis of proteome bound to D-loop region of mitochondrial DNA by DNA-linked affinity chromatography and reverse-phase liquid chromatography/tandem mass spectrometry. Ann NY Acad Sci, 1042:88–100. 2005.
40.
ClarkeRB. p27KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosis. Breast Cancer Res, 5:162–163. 2003.
41.
CofferPJ, JinJ, WoodgettJR. Protein kinase B (c-Akt): A multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J, 335:1–13. 1998.
42.
CohenP. Protein kinases—The major drug targets of the twenty-first century?Nature Rev Drug Discov, 1:309–315. 2002.
43.
CooperMA, SingletonVT. A survey of the 2001 to 2005 quartz crystal microbalance biosensor literature: Applications of acoustic physics to the analysis of biomolecular interactions. J Mol Recog, 20:154–184. 2007.
44.
CrossthwaiteAJ, HasanS, WilliamsRJ. Hydrogen peroxide-mediated phosphorylation of ERK1/2, Akt/PKB and JNK in cortical neurones: Dependence on Ca(2+) and PI3-kinase. J Neurochem, 80:24–35. 2002.
45.
CrowderRJ, FreemanRS. Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. J Neurosci, 18:2933–2943. 1998.
46.
DattaSR, BrunetA, GreenbergME. Cellular survival: A play in three Akts. Genes Dev, 13:2905–2927. 1999.
47.
DattaSR, DudekH, TaoX, MastersS, FuH, GotohY, GreenbergME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91:231–241. 1997.
48.
DavidGS, ChinoTH, ReisfeldRA. Binding of proteins to CNBr-activated sepharose 4B. FEBS Lett, 43:264–266. 1974.
49.
DavisRJ. Signal transduction by the JNK group of MAP kinases. Cell, 103:239–252. 2000.
50.
DeebO, ClareO. QSAR of aromatic substances: Protein tyrosine kinase inhibitory activity of flavonoid analogues. Chem Biol Drug Des, 70:437–449. 2007.
51.
del PesoL, Gonzalez–GarciaM, PageC, HerreraR, NunezG. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science, 278:687–689. 1997.
52.
DenleyA, KangS, KarstU, VogtPK. Oncogenic signaling of class I PI3K isoforms. Oncogene, 27:2561–2574. 2008.
53.
DhillonAS, MeikleS, YaziciZ, EulitzM, KolchW. Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J, 21:64–71. 2002.
54.
DixonMC. Quartz crystal microbalance with dissipation monitoring: Enabling real-time characterization of biological materials and their interactions. J Biomole Techn, 9:151–158. 2008.
55.
DixonSL, SmondyrevAM, KnollEH, RaoSN, ShawDE, FriesnerRA. PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des, 20:647–671. 2006.
56.
EnghRA, BossemeyerD.Structural aspects of protein kinase control. Role of conformational flexibility. Pharmacol Ther, 93:99–111. 2002.
57.
ErmakovaSP, ChoiBY, ChoiHS, KangBS, BodeAM, DongZ. The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J Biol Chem, 280:16882–16890. 2005.
58.
ErmakovaSP, KangBS, ChoiBY, ChoiHS, SchusterTF, MaWY, BodeAM, DongZ. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res, 66:9260–9269. 2006.
59.
FabbroD, RuetzS, BuchdungerE, Cowan–JacobSW, FendrichG, LiebetanzJ, MestanJ, O'ReillyT, TraxlerP, ChaudhuriB, FretzH, ZimmermannJ, MeyerT, CaravattiG, FuretP, ManleyPW. Protein kinases as targets for anticancer agents: From inhibitors to useful drugs. Pharmaco Ther, 93:79–98. 2002.
60.
FabianJR, DaarIO, MorrisonDK. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol, 13:7170–7179. 1993.
61.
FangJY, RichardsonBC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol, 6:322–327. 2005.
62.
FassihiA, SabetR. QSAR study of p56lck protein tyrosine kinase inhibitory activity of flavonoid derivatives using MLR and GA-PLS. Int J Mol Sci, 9:1876–1892. 2008.
63.
FavataMF, HoriuchiKY, ManosEJ, DaulerioAJ, StradleyDA, FeeserWS, Van DykDE, PittsWJ, EarlRA, HobbsF, CopelandRA, MagoldaRL, ScherlePA, TrzaskosJM. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem, 273:18623–18632. 1998.
64.
FavreauLV, PickettCB. The rat quinone reductase antioxidant response element: Identification of the nucleotide sequence required for basal and inducible activity and detection of antioxidant response element binding proteins in hepatoma and non-hepatoma cell lines. J Biol Chem, 270:24468–24474. 1995.
65.
FerriolaPC, CodyV, MiddletonEJr. Protein kinase C inhibition by plant flavonoids: Kinetic mechanisms and structure-activity relationships. Biochem Pharmacol, 38:1617–1624. 1989.
66.
FischmannTO, SmithCK, MayhoodTW, MyersJE, ReichertJP, MannarinoA, CarrD, ZhuH, WongJ, YangRS, LeHV, MadisonVS. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry, 48:2661–2674. 2009.
67.
FryDW, KrakerAJ, McMichaelA, AmbrosoLA, NelsonJM, LeopoldWR, ConnorsRW, BridgesAJ. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science, 265:1093–1095. 1994.
68.
FujimuraY, UmedaD, KiyoharaY, SunadaY, YamadaK, TachibanaH. The involvement of the 67 kDa laminin receptor-mediated modulation of cytoskeleton in the degranulation inhibition induced by epigallocatechin-3-O-gallate. Biochem Biophys Res Commu, 348:524–531. 2006.
69.
Gamet–PayrastreL, ManentiS, GratacapMP, TulliezJ, ChapH, PayrastreB. Flavonoids and the inhibition of PKC and PI 3-kinase. Gen Pharmacol, 32:279–286. 1999.
70.
GershteinES, ShatskayaVA, ErmilovaVD, KushliNE. Phosphatidylinositol 3-kinase expression in human breast cancer. Clin Chim Acta, 287:59–67. 1999.
71.
GunnRM, HailesHC. Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules. J Chem Biol, 1:49–62. 2008.
72.
HalliwellB, ZhaoK, WhitemanM. The gastrointestinal tract: A major site of antioxidant action?Free Radic Res, 33:819–830. 2000.
73.
Hall–JacksonCA, EyersPA, CohenP, GoedertM, BoyleFT, HewittN, PlantH, HedgeP. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol, 6:559–568. 1999.
74.
HanS, ZhouV, PanS, LiuY, HornsbyM, McMullanD, KlockHE, HaugenJ, LesleySA, GrayN, CaldwellJ, GuXJ. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg Med Chem Lett, 15:5467–5473. 2005.
75.
HanschC, HoekmanD, GaoH. Comparative QSAR: Toward a deeper understanding of chemicobiological interactions. Chem Rev, 96:1045–1075. 1996.
76.
HeZ, TangF, ErmakovaS, LiM, ZhaoQ, ChoYY, MaWY, ChoiHS, BodeAM, YangCS, DongZ. Fyn is a novel target of (-)-epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation. Mol Carcinog, 47:172–183. 2008.
77.
HigdonJV, FreiB. Coffee and health: A review of recent human research. Crit Rev Food Sci Nutr, 46:101–123. 2006.
78.
HillMM, HemmingsBA. Inhibition of protein kinase B/Akt. Implications for cancer therapy. Pharmacol Ther, 93:243–251. 2002.
79.
HollmanPC, KatanMB. Dietary flavonoids: Intake, health effects and bioavailability. Food Chem Toxicol, 37:937–942. 1999.
80.
HorvathCM, WenZ, DarnellJEJr. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev, 9:984–994. 1995.
81.
HouDX. Potential mechanisms of cancer chemoprevention by anthocyanins. Curr Mol Med, 3:149–159. 2003.
82.
HouDX, FujiiM, TeraharaN, YoshimotoN. Molecular mechanisms behind the chemopreventive effects of anthocyanidins (Review)J Biomed Biotech, 5:321–325. 2004.
83.
HouDX, KaiK, LiJJ, LinS, TeraharaN, WakamatsuM, FujiiM, YoungMR, ColburnN. Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure–activity relationship and molecular mechanisms. Carcinogenesis, 25:29–36. 2004.
84.
HouDX, OseT, LinS, HarazonoK, ImamuraI, KuboM, UtoT, TeraharaN, YoshimotoM, FujiiM. Anthocyanidins induce apoptosis in human promyelocytic leukemia cells: Structure–activity relationship and mechanisms involved. Int J Oncol, 23:705–712. 2003.
HuR, KongAN. Activation of MAP kinases, apoptosis and nutrigenomics of gene expression elicited by dietary cancer-prevention compounds. Nutrition, 20:83–88. 2004.
88.
HwangMK, KangNJ, HeoYS, LeeKW, LeeHJ. Fyn kinase is a direct molecular target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factor-alpha. Biochem Pharmacol, 77:1213–1222. 2009.
89.
HwangMK, SongNR, KangNJ, LeeKW, LeeHJ. Activation of phosphatidylinositol 3-kinase is required for tumor necrosis factor-alpha-induced upregulation of matrix metalloproteinase-9: Its direct inhibition by quercetin. Int J Biochem Cell Biol, 41:1592–1600. 2009.
90.
ImadaK, LeonardWJ. The Jak-STAT pathway. Mol Immunol, 37:1–11. 2000.
91.
InamdarNM, AhnYI, AlamJ. The heme-responsive element of the mouse heme oxygenase-1 gene is an extended AP-1 binding site that resembles the recognition sequences for MAF and NF-E2 transcription factors. Biochem Biophys Res Commun, 221:570–576. 1996.
92.
JelićD, MildnerB, KostrunS, NujićK, VerbanacD, CulićO, AntolovićR, BrandtW. Homology modeling of human Fyn kinase structure: Discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes. J Med Chem, 50:1090–1100. 2007.
93.
JinL, PluskeS, PetrellaEC, CantinSM, GorgaJC, RynkiewiczMJ, PandeyP, StricklerJE, BabineRE, WeaverDT, SeidlKJ. The three-dimensional structure of the ZAP-70 kinase domain in complex with staurosporine: Implications for the design of selective inhibitors. J Biol Chem, 279:42818–42825. 2004.
94.
JohnsonLN. Protein kinase inhibitors: Contributions from structure to clinical compounds. Q Rev Biophys, 42:1–40. 2009.
95.
JungSK, LeeKW, ByunS, KangNJ, LimSH, HeoYS, BodeAM, BowdenGT, LeeHJ, DongZ. Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res, 68:6021–6029. 2008.
96.
KangNJ, LeeKW, KwonJY, HwangMK, RogozinEA, HeoYS, BodeAM, LeeHJ, DongZ. Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling. Cancer Prev Res (Phila Pa), 1:522–531. 2008.
KangNJ, LeeKW, RogozinEA, ChoYY, HeoYS, BodeAM, LeeHJ, DongZ. Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J Biol Chem, 282:32856–32866. 2007.
99.
KangNJ, LeeKW, ShinBJ, JungSK, HwangMK, BodeAM, HeoYS, LeeHJ, DongZ. Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression. Carcinogenesis, 30:321–330. 2009.
100.
KarinM, CaoY, GretenFR, LiZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer, 2:301–310. 2002.
101.
KarlssonR. SPR for molecular interaction analysis: A review of emerging application areas. J Mol Recognit, 17:151–161. 2004.
102.
KhanN, AfaqF, SaleemM, AhmadN, MukhtarH. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res, 66:2500–2505. 2006.
103.
KimJE, KwonJY, LeeDE, KangNJ, HeoYS, LeeKW, LeeHJ. MKK4 is a novel target for the inhibition of tumor necrosis factor-alpha-induced vascular endothelial growth factor expression by myricetin. Biochem Pharmacol, 77:412–421. 2009.
104.
KimYC, MasutaniH, YamaguchiY, ItohK, YamamotoM, YodoiJ. Hemin-induced activation of the thioredoxin gene by Nrf2: A differential regulation of the antioxidant responsive element (ARE) by switch of its binding factors. J Biol Chem, 276:18399–18406. 2001.
105.
KinningsSL, JacksonRM. Binding site similarity analysis for the functional classification of the protein kinase family. J Chem Inf Model, 49:318–329. 2009.
106.
KirchmairJ, LaggnerC, WolberG, LangerT. Comparative analysis of protein-bound ligand conformations with respect to catalyst's conformational space subsampling algorithms. J Chem Inf Model, 45:422–430. 2005.
107.
KlampferL. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets, 6:107–121. 2006.
108.
KlausA, BirchmeierW. Wnt signalling and its impact on development and cancer. Nat Rev Cancer, 8:387–398. 2008.
109.
KobayashiS, JiH, YuzaY, MeyersonM, WongKK, TenenDG, HalmosB. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res, 65:7096–7101. 2005.
110.
KongAN, YuR, ChenC, MandlekarS, PrimianoT. Signal transduction events elicited by natural products: Role of MAPK and caspase pathways in homeostatic response and induction of apoptosis. Arch Pharm Res, 23:1–16. 2000.
111.
KubinyiH. Success stories of computer-aided design. Computer Applications in Pharmaceutical Research and Development. EkinsS.Wiley-Interscience: New York, 2006; 377–424.
112.
KumamotoT, FujiiM, HouDX. Myricetin directly targets JAK1 to inhibit cell transformation. Cancer Lett, 275:17–26. 2009.
113.
KumamotoT, FujiiM, HouDX. Akt is a direct target for myricetin to inhibit cell transformation. Mol Cell Biochem, 332:33–41. 2009.
KunduJK, SurhYJ. Cancer chemopreventive and therapeutic potential of resveratrol: Mechanistic perspectives. Cancer Lett, 269:243–261. 2008.
116.
KuoPC, AbeK, SchroederRA. Superoxide enhances interleukin 1beta-mediated transcription of the hepatocyte-inducible nitric oxide synthase gene. Gastroenterology, 118:608–618. 2000.
117.
LapennaS, GiordanoA. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov, 8:547–556. 2009.
118.
LaskowskiRA, GerickF, ThorntonJM. The structural basis of allosteric regulation in proteins. FEBS Lett, 583:1692–1698. 2009.
119.
LawrenceDS, NiuJ. Protein kinase inhibitors: The tyrosine-specific protein kinases. Pharmacol Ther, 77:81–114. 1998.
120.
LeeKW, KangNJ, HeoYS, RogozinEA, PuglieseA, HwangMK, BowdenGT, BodeAM, LeeHJ, DongZ. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res, 68:946–955. 2008.
121.
LeeKW, KangNJ, RogozinEA, KimHG, ChoYY, BodeAM, LeeHJ, SurhYJ, BowdenGT, DongZ. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis, 28:1918–1927. 2007.
122.
LeeKW, KangNJ, RogozinEA, OhSM, HeoYS, PuglieseA, BodeAM, LeeHJ, DongZ. The resveratrol analogue 3,5,3′,4′,5'-pentahydroxy-trans-stilbene inhibits cell transformation via MEK. Int J Cancer, 123:2487–2496. 2008.
123.
LinCH, YehSH, LinCH, LuKT, LeuTH, ChangWC, GeanPW. A role for the PI-3 kinase signaling pathway in fear conditioning and synaptic plasticity in the amygdala. Neuron, 31:841–851. 2001.
124.
LindsleyCW, ZhaoZ, LeisterWH, RobinsonRG, BarnettSF, Defeo–JonesD, JonesRE, HartmanGD, HuffJR, HuberHE, DugganME. Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett, 15:761–764. 2005.
125.
LiuY, GrayNS. Rational design of inhibitors that bind to inactive kinase conformations. Nature Chem Biol, 2:358–364. 2006.
126.
LosM, MaddikaS, ErbB, Schulze–OsthoffK. Switching Akt: From survival signaling to deadly response. BioEssays, 31:492–495. 2009.
127.
LuoZ, TzivionG, BelshawPJ, VavvasD, MarshallM, AvruchJ. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature, 383:181–185. 1996.
128.
LyonsJF, WilhelmS, HibnerB, BollagG. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer, 8:219–225. 2001.
129.
ManningG, WhyteDB, MartinezR, HunterT, SudarsanamS. The protein kinase complement of the human genome. Science, 298:1912–1934. 2002.
130.
MaroneyAC, FinnJP, Bozyczko–CoyneD, O'KaneTM, NeffNT, TolkovskyAM, ParkDS, YanCY, TroyCM, GreeneLA. CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. J Neurochem, 73:1901–1912. 1999.
131.
MartinGS. Cell signaling and cancer. Cancer Cell, 4:167–174. 2003.
132.
MatterWF, BrownRF, VlahosCJ. The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem Biophys Res Commun, 186:624–631. 1992.
133.
McCubreyJA, SteelmanLS, AbramsSL, LeeJT, ChangF, BertrandFE, NavolanicPM, TerrianDM, FranklinRA, D'AssoroAB, SalisburyJL, MazzarinoMC, StivalaF, LibraM. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul, 46:249–279. 2006.
134.
McCubreyJA, SteelmanLS, ChappellWH, AbramsSL, WongEW, ChangF, LehmannB, TerrianDM, MilellaM, TafuriA, StivalaF, LibraM, BaseckeJ, EvangelistiC, MartelliAM, FranklinRA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta, 1773:1263–1284. 2007.
135.
McDonnellJM. Surface plasmon resonance: Towards an understanding of the mechanisms of biological molecular recognition. Curr Opinion in Chem Biol, 5:572–577. 2001.
136.
McIntyreKW, ShusterDJ, GilloolyKM, DambachDM, PattoliMA, LuP, ZhouXD, QiuY, ZusiFC, BurkeJR. A highly selective inhibitor of IκB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum, 48:2652–2659. 2003.
137.
McMahonG, SunL, LiangC, TangC. Protein kinase inhibitors: Structural determinants for target specificity. Curr Opin Drug Discov Dev, 1:131–146. 1998.
138.
MencherSK, WangLG. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)BMC Clin Pharmacol, 5:1–7. 2005.
139.
MoinovaHR, MulcahyRT. An electrophile responsive element (EpRE) regulates beta-naphthoflavone induction of the human gammaglutamylcysteine synthetase regulatory subunit gene: Constitutive expression is mediated by an adjacent AP-1 site. J Biol Chem, 273:14683–14689. 1998.
140.
Molecular Operating Environment (MOE). Chemical Computing Group. www.chemcomp.comretrieved August 2007.
141.
MulcahyRT, GippJJ. Identification of a putative antioxidant response element in the 5′-flanking region of the human gammaglutamylcysteine synthetase heavy subunit gene. Biochem Biophys Res Commun, 209:227–233. 1995.
142.
MurakamiA, AshidaH, TeraoJ. Multitargeted cancer prevention by quercetin. Cancer Lett, 269:315–325. 2008.
143.
MyersMP, PassI, BattyIH, Van der KaayJ, StolarovJP, HemmingsBA, WiglerMH, DownesCP, TonksNK. The lipid phosphatase activity of PTEN is critical for its tumour suppressor function. Proc Natl Acad Sci USA, 95:13513–13518. 1998.
144.
NagarB, BornmannWG, PellicenaP, SchindlerT, VeachDR, MillerWT, ClarksonB, KuriyanJ. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)Cancer Res, 62:4236–4243. 2002.
145.
NewmanDJ, CraggGM, SnaderKM. Natural products as sources of new drugs over the period 1981–2002. J Nat Prod, 66:1022–1037. 2003.
146.
NicholsonKM, AndersonNG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal, 14:381–395. 2002.
147.
NkondjockA. Coffee consumption and the risk of cancer: An overview. Cancer Lett, 18:121–125. 2009.
148.
OblakM, RandicM, SolmajerT. Quantitative structure–activity relationship of flavonoid analogues. 3. Inhibition of p56lck protein tyrosine kinase. J Chem Inf Comput Sci, 40:994–1001. 2000.
OlayioyeMA, NeveRM, LaneHA, HynesNE. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J, 19:3159–3167. 2000.
151.
OngKC, KhooHE. Biological effects of myricetin. Gen Pharmacol, 29:121–126. 1997.
152.
OzesON, MayoLD, GustinJA, PfefferSR, PfefferLM, DonnerDB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature, 401:82–85. 1999.
153.
PearsonG, BumeisterR, HenryDO, CobbMH, WhiteMA. Uncoupling Raf1 from MEK1/2 impairs only a subset of cellular responses to Raf activation. J Biol Chem, 275:37303–37306. 2000.
154.
PerkintonMS, SihraTS, WilliamsRJ. Ca(2+)-permeable AMPA receptors induce phosphorylation of cAMP response element-binding protein through a phosphatidylinositol 3-kinase-dependent stimulation of the mitogen-activated protein kinase signaling cascade in neurons. J Neurosci, 19:5861–5874. 1999.
RabindranSK, DiscafaniCM, RosfjordEC, BaxterM, FloydMB, GolasJ, HallettWA, JohnsonBD, NilakantanR, OverbeekE, ReichMF, ShenR, ShiX, TsouHR, WangYF, WissnerA. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res, 64:3958–3965. 2004.
165.
RenY, SmithA. Mechanism of metallothionein gene regulation by heme–hemopexin: Roles of protein kinase C, reactive oxygen species, and cis-acting elements. J Biol Chem, 270:23988–23995. 1995.
166.
RicciF, VolpeG, MicheliL, PalleschiG. A review on novel developments and applications of immunosensors in food analysis. Analyt Chimica Acta, 605:111–129. 2007.
167.
Rice–EvansC. Flavonoid antioxidants. Curr Med Chem, 8:797–807. 2001.
Rice–EvansCA, MillerNJ, PagangaG. Structure–antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med, 20:933–956. 1996.
170.
RobertsPJ, DerCJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26:3291–3310. 2007.
171.
RomashkovaJA, MakarovSS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature, 401:86–90. 1999.
172.
RommelC, ClarkeBA, ZimmermannS, NuñezL, RossmanR, ReidK, MoellingK, YancopoulosGD, GlassDJ. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science, 286:1738–1741. 1999.
173.
RushmoreTH, KingRG, PaulsonKE, PickettCB. Regulation of glutathione S-transferase Ya subunit gene expression: Identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc Natl Acad Sci USA, 87:3826–3830. 1990.
174.
SalmondRJ, FilbyA, QureshiI, CasertaS, ZamoyskaR. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev, 228:9–22. 2009.
SchweizerA. Roschitzki–Voser H, Amstutz P, Briand C, Gulotti–Georgieva M, Prenosil E, Binz HK, Capitani G, Baici A, Plückthun A, and Grütter MG. Inhibition of caspase-2 by a designed ankyrin repeat protein: Specificity, structure, and inhibition mechanism. Structure, 15:625–636. 2007.
181.
Sebolt–LeopoldJS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene, 19:6594–6599. 2000.
182.
Sebolt–LeopoldJS, HerreraR. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer, 4:937–947. 2004.
183.
SegerR, KrebsEG. The MAPK signaling cascade. FASEB J, 9:726–735. 1995.
184.
ShakibaeiM, HarikumarKB, AggarwalBB. Resveratrol addiction: To die or not to die. Mol Nutr Food Res, 53:115–128. 2009.
185.
ShchemelininI, ŠefcL, NečasE. Protein kinases, their functions and implication in cancer and other diseases. Folia Biol (Praha), 52:81–101. 2006.
186.
SheQB, MaWY, WangM, KajiA, HoCT, DongZ. Inhibition of cell transformation by resveratrol and its derivatives: Differential effects and mechanisms involved. Oncogene, 22:2143–2150. 2003.
187.
SheltonJG, MoyePW, SteelmanLS, BlalockWL, LeeJT, FranklinRA, McMahonM, McCubreyJA. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia, 17:1765–1782. 2003.
188.
ShibaY, KinoshitaT, ChumanH, TaketaniY, TakedaE, KatoY, NaitoM, KawabataK, IshisakaA, TeraoJ, KawaiY. Flavonoids as substrates and inhibitors of myeloperoxidase: Molecular actions of aglycone and metabolites. Chem Res Toxico, 21:1600–1609. 2008.
189.
ShimJH, ChoiHS, PuglieseA, LeeSY, ChaeJI, ChoiBY, BodeAM, DongZ. (-)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase. J Biol Chem, 283:28370–28379. 2008.
190.
ShishodiaS, AggarwalBB. Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem, 279:47148–47158. 2004.
191.
ShuaiK, HorvathCM, HuangLH, QureshiSA, CowburnD, DarnellJEJr. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell, 76:821–828. 1994.
192.
SmythLA, CollinsI. Measuring and interpreting the selectivity of protein kinase inhibitors. J Chem Biol, 2:131–151. 2009.
193.
SohY, JeongKS, LeeIJ, BaeMA, KimYC, SongBJ. Selective activation of the c-Jun N-terminal protein kinase pathway during 4-hydroxynonenal-induced apoptosis of PC12 cells. Mol Pharmacol, 58:535–541. 2000.
194.
SpencerJP, Rice–EvansC, WilliamsRJ. Modulation of pro-survival Akt/PKB and ERK1/2 signalling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability. J Biol Chem, 278:34783–34793. 2003.
195.
SpencerJP, SchroeterH, CrossthwaitheAJ, KuhnleG, WilliamsRJ, Rice-EvansC. Contrasting influences of glucuronidation and O-methylation of epicatechin on hydrogen peroxide-induced cell death in neurons and fibroblasts. Free Radic Biol Med, 31:1139–1146. 2001.
196.
SpencerJP, SchroeterH, KuhnleG, SraiSK, TyrrellRM, HahnU, Rice–EvansC. Epicatechin and its in vivo metabolite, 3V-O-methyl epicatechin, protect human fibroblasts from oxidative-stress-induced cell death involving caspase-3 activation. Biochem J, 354:493–500. 2001.
197.
StieweT. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer, 7:165–168. 2007.
198.
SurhYJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer, 3:768–780. 2003;
199.
SweattJD. Memory mechanisms: The yin and yang of protein phosphorylation. Curr Biol, 11:R391–R394. 2001.
200.
TachibanaH, KogaK, FujimuraY, YamadaK. A receptor for green tea polyphenol EGCG. Nat Struct Mol Biol, 11:380–381. 2004.
201.
TeilletF, BoumendjeA, BoutonnatJ, RonotX. Flavonoids as RTK inhibitors and potential anticancer agents. Med Res Reviews, 28:715–745. 2008.
202.
TorresM, FormanHJ. Redox signaling and the MAP kinase pathways. Biofactors, 17:287–296. 2003.
203.
TraxlerP, FuretP. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther, 82:195–206. 1999.
204.
TsujiY, AyakiH, WhitmanSP, MorrowCS, TortiSV, TortiFM. Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol, 20:5818–5827. 2000.
205.
TurksonJ, JoveR. STAT proteins: Novel molecular targets for cancer drug discovery. Oncogene, 19:6613–6626. 2000.
206.
UedaS, MasutaniH, NakamuraH, TanakaT, UenoM, YodoiJ. Redox control of cell death. Antioxid Redox Signal, 4:405–414. 2002.
207.
VanScyocWS, HoldgateGA, SullivanJE, WardWH. Enzyme kinetics and binding studies on inhibitors of MEK protein kinase. Biochemistry, 47:5017–5027. 2008.
208.
VenterJC, AdamsMD, MyersEWet al.The sequence of the human genome. Science, 291:1304–1351. 2001.
209.
VlahosCJ, MatterWF, HuiKY, BrownRF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)J Biol Chem, 18:5241–5248. 1994.
210.
VirgiliF, MarinoM. Regulation of cellular signals from nutritional molecules: A specific role for phytochemicals, beyond antioxidant activity. Free Radical Biol Med, 45:1205–1216. 2008.
211.
WagnerEF, NebredaAR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer, 9:537–549. 2009.
212.
WalkerEH, PacoldME, PerisicO, StephensL, HawkinsPT, WymannMP, WilliamsRL. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell, 6:909–919. 2000.
213.
WanPT, GarnettMJ, RoeSM, LeeS, Niculescu–DuvazD, GoodVM, JonesCM, MarshallCJ, SpringerCJ, BarfordD, MaraisR. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 116:855–867. 2004.
214.
WangLS, StonerGD. Anthocyanins and their role in cancer prevention. Cancer Lett, 269:281–290. 2008.
215.
WegenerJ. Janshoff A, and Steinem C. The quartz crystal microbalance as a novel means to study cell–substrate interactions in situ. Cell Biochem Biophy, 34:121–131. 2001.
216.
WeisburgerJH. Chemopreventive effects of cocoa polyphenols on chronic diseases. Exp Biol Med (Maywood), 226:891–897. 2001.
217.
WenZ, DarnellJEJr. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res, 25:2062–2067. 1997.
218.
WenZ, ZhongZ, DarnellJEJr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell, 82:241–250. 1995.
219.
WhitmarshAJ, DavisRJ. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene, 26:3172–3184. 2007.
WolberG, KosaraR. Pharmacophores from macromolecular complexes with Ligand Scout. Pharmacophores and Pharmacophore Searches, 32LangerT., HoffmannR.D.Wiley-VCH, 2006; 131–150.
222.
WolberG, LangerT. Ligand Scout: 3D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model, 45:160–169. 2005.
223.
WolberG, SeidelT, BendixF, LangerT. Molecule-pharmacophore superpositioning and pattern matching. Drug Discov Today, 13:23–29. 2008.
224.
WuX, SenechalK, NeshatMS, WhangYE, SawyersCL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA, 95:15587–15591. 1998.
225.
XuX, SunYL, HoeyT. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science, 273:794–797. 1996.
YanJ, RoyS, ApolloniA, LaneA, HancockJF. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem, 273:24052–24056. 1998.
228.
YangCS, MaliakalP, MengX. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol, 42:25–54. 2002.
229.
YangCS, WangZY. Tea and Cancer. J Natl Cancer Inst, 85:1038–1049. 1993.
230.
YeungK, SeitzT, LiS, JanoschP, McFerranB, KaiserC, FeeF, KatsanakisKD, RoseDW, MischakH, SedivyJM, KolchW. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature, 401:173–177. 1999.
231.
YoshiokaK, DengT, CavigelliM, KarinM. Antitumor promotion by phenolic antioxidants: Inhibition of AP-1 activity through induction of Fra expression. Proc Natl Acad Sci USA, 92:4972–4976. 1995.
232.
YuanJP, WangJH, LiuX. Metabolism of dietary soy isoflavones to equol by human intestinal microflora. Implications for health. Mol Nutr Food Res, 51:765–781. 2007.
233.
YuanTL, CantleyLC. PI3K pathway alterations in cancer: Variations on a theme. Oncogene, 27:5497–5510. 2008.
234.
ZaveriNT. Green tea and its polyphenolic catechins: Medicinal uses in cancer and noncancer applications. Life Sci, 78:2073–2080. 2006.
235.
ZhaJ, HaradaH, YangE, JockelJ, KorsmeyerSJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)Cell, 87:619–628. 1996.
236.
ZhangJ, YangPL, NathanaelS, GrayNS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer, 9:28–39. 2009.
